ERBB2 and breast cancer: OBJECTIVE: To evaluate the predictive value of the mean platelet volume–to–albumin (MPV/Alb) ratio for pathological complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) treated with neoadjuvant chemotherapy (NACT).